Chemotherapy is commonly used in the treatment of ovarian cancer, yet most ovarian cancers harbor inherent resistance or develop acquired resistance. Therefore, novel therapeutic approaches to overcome chemoresistance are required. In this study, we developed a hyaluronic acid-labeled poly(d,l-lactide-co-glycolide) nanoparticle (HA-PLGA-NP) encapsulating both paclitaxel (PTX) and focal adhesion kinase (FAK) siRNA as a selective delivery system against chemoresistant ovarian cancer. The mean size and zeta potential of the HA-PLGA-NP were 220 nm and -7.3 mV, respectively. Incorporation efficiencies for PTX and FAK siRNA in the HA-PLGA-NPs were 77% and 85%, respectively. HA-PLGA-NP showed higher binding efficiency for CD44-positive tumor cells as compared with CD44-negative cells. HA-PLGA (PTX+FAK siRNA)-NP caused increased cytotoxicity and apoptosis in drug-resistant tumor cells. Treatment of human epithelial ovarian cancer tumor models HeyA8-MDR ( < 0.001) and SKOV3-TR ( < 0.001) with HA-PLGA (PTX+FAK siRNA)-NP resulted in significant inhibition of tumor growth. Moreover, in a drug-resistant, patient-derived xenograft (PDX) model, HA-PLGA (PTX+FAK siRNA)-NP significantly inhibited tumor growth compared with PTX alone ( < 0.002). Taken together, HA-PLGA-NP acts as an effective and selective delivery system for both the chemotherapeutic and the siRNA in order to overcome chemoresistance in ovarian carcinoma. These findings demonstrate the efficacy of a novel, selective, two-in-one delivery system to overcome chemoresistance in epithelial ovarian cancer. .

Background and Aims Although recent studies have reported that inflammatory bowel disease (IBD) is associated with the development of neurodegenerative diseases via chronic intestinal inflammation and the gut-brain axis, there is insufficient evidence supporting this notion. The aim of this study was to determine the risk of neurodegenerative diseases including Parkinson’s disease (PD) and Alzheimer’s disease (AD) in patients with IBD. Methods Using the National Health Insurance Service data for the entire Korean population, we identified patients with IBD and controls from 2009 to 2011 and followed them up until 2017. We selected the controls in a 1:4 ratio based on age and sex for comparison with cases. Results Of 24,830 IBD patients and 99,320 non-IBD controls, 98 IBD patients and 256 controls developed PD, while 644 IBD patients and 2,303 controls developed AD. The overall neurodegenerative disease risk was higher in IBD patients [PD: adjusted hazard ratio (HR), 1.56; 95% confidence interval (CI), 1.24-1.97; AD: adjusted HR, 1.14; 95% CI, 1.05-1.25). Younger IBD patients aged 40-65 years had a higher risk of PD compared to controls (adjusted HR, 2.34; 1.63-3.35)]. In contrast, patients aged ≥65 years had an increased risk of AD compared to controls (adjusted HR, 1.14; 1.04-1.25). In a nested case-control study of the IBD cohort, patients aged ≥65 years and the female sex were risk factors for AD, while living in an urban area was protective against AD. Conclusions The risk of neurodegenerative diseases was higher in IBD patients than in the non-IBD population.

Dentritic cell (DC)-based cancer immunotherapy faces challenges in both efficacy and practicality. However, DC-based vaccination requires multiple injections and elaborates ex vivo manipulation, which substantially limits their use. Therefore, we sought to develop a chitosan nanoparticle (CH-NP)-based platform for the next generation of vaccines to bypass the ex vivo manipulation and induce immune responses via active delivery of polyinosinic-polycytidylic acid sodium salt (poly I:C) to target Toll-like receptor 3 (TLR3) in endosomes. We developed CH-NPs encapsulating ovalbumin (OVA) as a model antigen and poly I:C as the adjuvant in an ionic complex. These CH-NPs showed increased in vivo intracellular delivery to the DCs in comparison with controls after injection into tumor-bearing mice, and promoted DC maturation, leading to emergence of antigen-specific cytotoxic CD8+ T cells. Finally, the CH-NPs showed significantly greater antitumor efficacy in EG.7 and TC-1 tumor-bearing mice compared to the control (p < 0.01). Taken together, these data show that the CH-NP platform can be used as an immune response modulatory vaccine for active cancer immunotherapy without ex vivo manipulation, thus resulting in increased anticancer efficacy.

In this study we investigated bacterial and cell adhesion to poly(propylene carbonate) (PPC) films, that had been synthesized by the copolymerization of carbon dioxide (a global warming chemical) with propylene oxide. We also assessed the biocompatibility and biodegradability of the films in vivo, and their oxidative degradation in vitro. The bacteria adhered to the smooth, hydrophobic PPC surface after 4 h incubation. Pseudomonas aeruginosa and Enterococcus faecalis had the highest levels of adhesion, Escherichia coli and Staphylococcus aureus had the lowest levels, and Staphylococcus epidermidis was intermediate. In contrast, there was no adhesion of human cells (cell line HEp-2) to the PPC films, due to the hydrophobicity and dimensional instability of the surface. On the other hand, the PPC films exhibited good biocompatibility in the mouse subcutaneous environment. Moreover, contrary to expectation the PPC films degraded in the mouse subcutaneous environment. This is the first experimental confirmation that PPC can undergo surface erosion biodegradation in vivo. The observed biodegradability of PPC may have resulted from enzymatic hydrolysis and oxidative degradation processes. In contrast, the PPC films showed resistance to oxidative degradation in vitro. Overall, PPC revealed high affinity to bioorganisms and also good biodegradability.